Retractable Technologies (RVP) AI Stock Analysis

Compare

429 Followers

RVP Dividends

Top Page

Retractable Technologies

(NYSE MKT:RVP)

47Neutral

Retractable Technologies' overall stock performance is challenged by declining financial metrics, with significant issues in revenue and profitability. The stock also exhibits weak technical indicators and a negative P/E ratio, hampering its attractiveness. The stable balance sheet and manageable debt levels offer some support, but the overall outlook remains cautious due to the need for improved financial performance.

Retractable Technologies (RVP) vs. S&P 500 (SPY)

Market Cap

$20.88M

Dividend YieldN/A

Average Volume (3M)34.14K

Price to Earnings (P/E)―

Beta (1Y)0.66

Revenue Growth-24.19%

EPS Growth-67.34%

CountryUS

Employees221

SectorHealthcare

Sector Strength66

IndustryMedical - Instruments & Supplies

Share Statistics

EPS (TTM)-0.40

Shares Outstanding29,937,159

10 Day Avg. Volume44,566

30 Day Avg. Volume34,142

Financial Highlights & Ratios

PEG RatioN/A

Price to Book (P/B)N/A

Price to Sales (P/S)0.59

Price to Cash Flow (P/CF)-1.00

P/FCF Ratio0.00

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price TargetN/A

Price Target UpsideN/A

Rating ConsensusN/A

Number of Analyst Covering0

Retractable Technologies Business Overview & Revenue Model

Company DescriptionRetractable Technologies, Inc. (RVP) is a medical device company specializing in the design, development, and manufacturing of safety-engineered medical products. The company primarily operates in the healthcare sector, focusing on the production of retractable safety syringes and other safety medical devices aimed at reducing the risk of needlestick injuries and cross-contamination, thereby enhancing patient and healthcare worker safety.

How the Company Makes MoneyRetractable Technologies generates revenue through the sale of its safety-engineered medical products, particularly its retractable safety syringes. The company sells these products to healthcare providers, hospitals, and clinics, as well as through distribution partnerships with medical supply companies. Revenue is driven by product sales, and any significant partnerships with large healthcare organizations or distributors can have a substantial impact on earnings. The adoption of safety regulations and standards in healthcare settings that prioritize needlestick prevention also serves as a critical factor contributing to the company's revenue growth.

Retractable Technologies Financial Statement Overview

Summary

Retractable Technologies faces significant challenges with declining revenues and profitability issues impacting the income statement. The balance sheet remains stable with manageable debt levels, but declining cash reserves and assets could become a concern. Cash flow stability is uncertain due to inconsistent free cash flow performance. The company needs to address revenue generation and cost management to improve financial health.

Income Statement

Neutral

The income statement shows a significant decline in revenue over recent years, with 2024 experiencing no revenue. Gross profit has turned negative, and net income has been consistently negative for the past three years, indicating profitability issues. Margins have shrunk significantly, turning negative, which reflects operational challenges and increased costs relative to revenue.

Balance Sheet

Positive

The balance sheet reveals a relatively stable equity position, though there is a slight decline in stockholders' equity. The debt-to-equity ratio remains low, indicating manageable leverage levels. However, the decrease in total assets and cash reserves could pose a risk if financial performance does not improve.

Cash Flow

Neutral

Cash flow analysis indicates stable operating cash flow despite declining revenues, but free cash flow has fluctuated significantly, turning negative at times. The cash flow to net income ratios are inconsistent, reflecting challenges in converting earnings into cash. Continued negative free cash flow could impact future liquidity.

TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Breakdown
Income Statement		Total Revenue
38.27M	0.00	43.60M	94.82M	188.38M	81.86M
	Gross Profit
3.01M	-1.03M	9.11M	28.25M	95.35M	37.01M
	EBIT
-16.66M	-21.11M	-11.49M	2.99M	72.60M	24.07M
	EBITDA
178.62K	-21.11M	-1.24M	9.94M	76.44M	27.17M
	Net Income Common Stockholders
-15.73M	-11.89M	-7.01M	5.08M	56.06M	24.22M
Balance Sheet		Cash, Cash Equivalents and Short-Term Investments
19.32M	4.24M	47.29M	49.38M	42.43M	25.65M
	Total Assets
51.51M	160.72M	179.67M	195.67M	206.30M	104.97M
	Total Debt
7.31M	332.48K	1.54M	1.82M	2.10M	3.74M
	Net Debt
-12.01M	-3.90M	-11.13M	-17.90M	-27.06M	-13.83M
	Total Liabilities
17.18M	73.55M	80.38M	89.13M	107.14M	55.09M
	Stockholders Equity
34.32M	87.17M	99.29M	106.54M	99.17M	49.88M
Cash Flow		Free Cash Flow
-9.85M	1.91M	1.91M	-61.95K	-25.57M	-2.05M
	Operating Cash Flow
-8.56M	2.77M	2.77M	16.77M	32.79M	19.00M
	Investing Cash Flow
1.75M	-10.76M	-10.76M	-31.20M	-63.04M	-19.33M
	Financing Cash Flow
-534.79K	941.64K	941.64K	4.99M	41.84M	11.96M

Retractable Technologies Technical Analysis

Technical Analysis Sentiment

Negative

Last Price0.69

Price Trends

50DMA

0.75

Negative

100DMA

0.73

Negative

200DMA

0.81

Negative

Market Momentum

MACD

-0.01

Negative

RSI

43.76

Neutral

STOCH

41.27

Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For RVP, the sentiment is Negative. The current price of 0.69 is below the 20-day moving average (MA) of 0.71, below the 50-day MA of 0.75, and below the 200-day MA of 0.81, indicating a bearish trend. The MACD of -0.01 indicates Negative momentum. The RSI at 43.76 is Neutral, neither overbought nor oversold. The STOCH value of 41.27 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for RVP.

Retractable Technologies Risk Analysis

Retractable Technologies disclosed 17 risk factors in its most recent earnings report. Retractable Technologies reported the most risks in the “Macro & Political” category.

Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy

Latest Risks Added 0 New Risks

Retractable Technologies Peers Comparison

Overall Rating

UnderperformOutperform

Sector (50)

Financial Indicators

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
MHUA	57 Neutral	$7.49M	0.76	6.43%	―	-2.53%	34.36%
Sector *	50 Neutral	$5.14B	3.10	-40.94%	2.95%	17.94%	2.00%
RVP	47 Neutral	$20.88M	―	-12.75%	―	-24.19%	-67.34%
MLSS	44 Neutral	$71.54M	―	-68.09%	―	-12.19%	36.73%
AKYA	39 Underperform	$54.82M	―	-180.44%	―	-15.48%	24.53%
FEMY	39 Underperform	$32.58M	―	-182.18%	―	51.97%	9.94%

* Healthcare Sector Average

Performance Comparison

RVP

Retractable Technologies

0.72

-0.35

-32.71%

MLSS

Milestone Scientific

0.91

0.35

62.50%

AKYA

Akoya Biosciences

1.10

-2.71

-71.13%

FEMY

Femasys

1.22

-0.11

-8.27%

MHUA

Meihua International Medical Technologies Co., Ltd.

0.31

-0.37

-54.41%

Glossary

OutperformA stock rated as "Outperform" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock is likely to deliver higher returns compared to the average returns of other stocks in the same sector or market index. Investors might consider this stock a good buying opportunity.

NeutralA stock rated as "Neutral" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly attractive nor unattractive for investment. Investors may consider holding onto the stock, as it is not expected to either significantly outperform or underperform the market.

UnderperformA stock rated as "Underperform" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock may deliver lower returns compared to the average returns of other stocks in the same sector or market index. Investors might consider selling the stock or avoiding it as an investment.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.